Compare Kimberly Clark Corp (KMB) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs Koninklijke Philips NV — how do they compare? Kimberly Clark Corp trades at $109.24 (market cap $36.11B), while Koninklijke Philips NV trades at $26.84 (market cap $26.58B). The key difference: Kimberly Clark Corp is the larger of the two by market cap, and Kimberly Clark Corp pays the higher dividend (4.72%). Which is the better fit depends on your goals.
| KMB | PHG | |
|---|---|---|
Market Cap | $36.11B | $26.58B |
Sector | Consumer Staples | Health |
52-Week High | $134.81 | $32.91 |
52-Week Low | $93.05 | $25.02 |
Enterprise Value | $41.67B | $33.13B |
Dividend Yield | 4.72% | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $109.47, up 1.34% today, with a neutral technical signal and bearish moving averages. Recent Q2 2026 earnings missed estimates due to China diaper disruptions and a distribution center fire, though gross margin expanded. The company maintains a strong dividend yield of 4.7% and an A credit rating. Analyst consensus is a $113.20 price target with 29% buy ratings, but near-term headwinds include softer consumer demand and inventory adjustments.
Outlook remains cautious with 2026 guidance trimmed; the stock offers value at a forward P/E of 14.6x and robust cash flow, but risks from China market volatility and input cost pressures persist. Institutional interest is mixed, with recent filings showing both new positions and trims. Long-term prospects hinge on innovation and productivity gains offsetting cyclical challenges.
PHG trades at $26.77, down 0.63% on the day, with a bullish technical signal supported by moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and a return to profitability in 2025 after previous losses. Recent news highlights Exor's potential stake increase to 22% and FDA clearances for new medical devices, supporting positive sentiment.
The outlook remains constructive with 41% analyst buy ratings and no sell recommendations, though near-term risks include order timing volatility and China market weakness. Earnings momentum and institutional accumulation provide support, while valuation appears reasonable at P/E 20.53 and P/S 1.28 relative to sector peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
